[NFS-01] Neuroscience Frontier Symposium 01
New approaches aimed for the development of disease modifying therapies of Alzheimer's disease and other dementia diseases

[NFS-01-2] Principles of Inflammasome Priming and Inhibition: Implications for Neurodegenerative Disorders

^○Giulio M. Pasinetti^1,2 (1.Icahn School of Medicine at Mount Sinai, USA, 2.James J Peters Veterans Affairs Medical Center, USA)

Alzheimer's disease (AD) is the most common neurodegenerative disorder and affects over 40 million patients worldwide, but no causative or preventive treatment is currently available. However, recent researches have gradually elucidated new pathogenesis of AD and other dementia disease, and researches linking to disease modification therapies (DMTs) are also progressing. In this symposium, we introduce cutting-edge approaches for DMTs development of AD and other demnetia diseases, and discuss their translational possibilities and issues to be resolved.

Dr. Giulio Maria Pasinetti is the The Saunders Family Chair and Professor of Neurology, Neuroscience, and Geriatrics and Adult Development at the Ichan School of Medicine at Mount Sinai (ISMMS) in NY. He also serves as the Director of Basic and Biomedical Research in the Center for Geriatic Research and Training at the Bronx Veterans Affairs Medical Center. He is also the Director of the Center for Molecular Integrative Neuroresilience at the ISMMS. The Center’s goal is to understand the mechanisms of action through which novel therapeutics act against stressful events and to clarify the role of innate immunity in the gut/microbiome-brain axis at the genomic level in the promotion of cognitive and psychological resilience across the lifespan.